These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25735646)

  • 1. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.
    Wade JR; Parker G; Kosutic G; Feagen BG; Sandborn WJ; Laveille C; Oliver R
    J Clin Pharmacol; 2015 Aug; 55(8):866-74. PubMed ID: 25735646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.
    Vande Casteele N; Mould DR; Coarse J; Hasan I; Gils A; Feagan B; Sandborn WJ
    Clin Pharmacokinet; 2017 Dec; 56(12):1513-1523. PubMed ID: 28353055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
    Vande Casteele N; Feagan BG; Vermeire S; Yassine M; Coarse J; Kosutic G; Sandborn WJ
    Aliment Pharmacol Ther; 2018 Jan; 47(2):229-237. PubMed ID: 29159893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.
    Sandborn WJ; Wolf DC; Kosutic G; Parker G; Schreiber S; Lee SD; Abraham B; Afzali A; Arsenescu RI; Gutierrez A; Spearman M; Coarse J; Feagan BG
    Inflamm Bowel Dis; 2017 Jul; 23(7):1047-1056. PubMed ID: 28410341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
    Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol in the treatment of Crohn's disease.
    Ferrante M; Vermeire S; Rutgeerts P
    Expert Opin Biol Ther; 2013 Apr; 13(4):595-605. PubMed ID: 23451881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
    Vavricka SR; Spasojevic M; Rogler G; Schoepfer AM; Seibold F; Borovicka J; Frei P; Zeitz J; Greuter T; Manser C; Scharl M; Misselwitz B; Straumann A; Michetti P; Biedermann L;
    Dig Dis; 2017; 35(5):423-432. PubMed ID: 28595194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.
    Moon W; Pestana L; Becker B; Loftus EV; Hanson KA; Bruining DH; Tremaine WJ; Kane SV
    Aliment Pharmacol Ther; 2015 Aug; 42(4):428-40. PubMed ID: 26081839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
    Sandborn WJ; Schreiber S; Feagan BG; Rutgeerts P; Younes ZH; Bloomfield R; Coteur G; Guzman JP; D'Haens GR
    Clin Gastroenterol Hepatol; 2011 Aug; 9(8):670-678.e3. PubMed ID: 21642014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
    Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
    RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease.
    Lefevre PLC; Dulai PS; Wang Z; Guizzetti L; Feagan BG; Pop A; Yassine M; Shackelton LM; Jairath V; Sandborn WJ; Vande Casteele N
    BioDrugs; 2022 Jan; 36(1):85-93. PubMed ID: 34951696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
    Sandborn WJ; Melmed GY; McGovern DP; Loftus EV; Choi JM; Cho JH; Abraham B; Gutierrez A; Lichtenstein G; Lee SD; Randall CW; Schwartz DA; Regueiro M; Siegel CA; Spearman M; Kosutic G; Pierre-Louis B; Coarse J; Schreiber S
    Aliment Pharmacol Ther; 2015 Aug; 42(3):330-42. PubMed ID: 26031921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
    Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
    Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
    Tun GS; Lobo AJ
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol.
    Melmed GY; McGovern D; Schreiber S; Kosutic G; Spearman M; Coarse J; Sandborn WJ
    Curr Med Res Opin; 2016 Dec; 32(12):1937-1941. PubMed ID: 27494777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
    Vavricka SR; Schoepfer AM; Bansky G; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Scharl M; Seibold F; Straumann A; Michetti P;
    Inflamm Bowel Dis; 2011 Jul; 17(7):1530-9. PubMed ID: 21674709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
    Lee SD; Rubin DT; Sandborn WJ; Randall C; Younes Z; Schreiber S; Schwartz DA; Burakoff R; Binion D; Dassopoulos T; Arsenescu R; Gutierrez A; Scherl E; Kayhan C; Hasan I; Kosutic G; Spearman M; Sen D; Coarse J; Hanauer S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1870-80. PubMed ID: 27400222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.